Health AI Central
Share:
Peer-Reviewed Publication
Diabetes Technol Ther2026;15209156261481250.August 20, 2026Letter

Letter: Authors' Response to LTE by Scaramuzza et al.

Maya Laron-Hirsh1, Sapir Barel1, Anirban Roy2, George Mallas2, Benyamin Grossman2, Robert A Vigersky2, Ohad Cohen2, Amir Tirosh1
1Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel.
2Medtronic, Closed-loop Development, Northridge, California, USA.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.